Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | LONP1 | P36776 | 2/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6706897 | 0.78 | KCNA5 (0.47) | CYP2D6CYP2C9CYP2C19KDM4ERAB9A | |
| SCHEMBL19003627 | 0.72 | POLB (0.35) | ATMCYP2D6CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL18595067 | 0.71 | SMN1; SMN2 (0.37) | ATMCYP2D6CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL18881769 | 0.69 | ATM (0.34) | ATMCYP2D6CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL7973738 | 0.69 | KDM4E (0.40) | ATMCYP2D6CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL5159765 | 0.69 | CYP2D6 (0.33) | ATMCYP2D6CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL7719082 | 0.68 | ATM (0.36) | ATMKDM4ERAB9ASMN1; SMN2 | |
| SCHEMBL9029684 | 0.68 | PRSS1 (0.37) | — | |
| SCHEMBL9474488 | 0.68 | RAB9A (0.38) | ATMKDM4ERAB9ASMN1; SMN2 | |
| SCHEMBL28802112 | 0.67 | KDM4E (0.32) | ATMCYP2D6CYP19A1CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040019068-A1 | Novel remedies or preventives for angiostenosis | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2004-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040019068-A1 | Novel remedies or preventives for angiostenosis | CMA1, ACE, AGTR1 | ATM 3763/4885CYP2D6 3461/4885CYP19A1 2226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.